PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Vancomycin

Drugs in development · updated 30 October 2026

Vancomycin: clinical trials and development status

Other names and codes: Tyzavan, Firvanq Kit

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Vancomycin is in 40 active clinical trials (recruiting or ongoing, phases I–III) for 34 diseases. The most advanced phase is III.

40Active trials
IIIMost advanced phase
34Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Vancomycin and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 34 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Clostridium InfectionsIII2NCT05266807
Capsular contractureIII1NCT04731025
Enterocolitis, PseudomembranousIII1NCT07328971
Fractures, OpenIII1NCT07659886
InfectionIII1NCT05959603
OsteomyelitisIII1NCT07435051
Postoperative complicationsII–III1NCT05625373
Tibial FracturesIII1NCT05766670
Sclerosing cholangitisII5NCT07341282
Ulcerative colitisII3NCT07341282
Alopecia areataII1NCT06747611
Alopecia universalisII1NCT06747611
Attention deficit hyperactivity disorderII1NCT07756255
Autism spectrum disorderII1NCT03408886
ColitisII1NCT07646223
Colorectal neoplasmII1NCT04729322
Crohn's diseaseII1NCT07300553
Digestive System DiseasesII1NCT05876182
Gastrointestinal diseaseII1NCT03408886
Growth disorderII1NCT07207434
Hepatocellular carcinomaII1NCT05690048
Hip osteoarthritisII1NCT05169229
HypersensitivityI–II1NCT07605806
Inflammatory bowel diseasesII1NCT05876182
Neurodevelopmental disorderII1NCT07756255
Biliary atresiaI1NCT02137668
Diffuse large B-cell lymphomaI1NCT07478848
Heart failureI1NCT07490054
MelanomaI1NCT06540391
Multiple sclerosisI1NCT05539729

Everything on Vancomycin

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch